Virgin Group Fund Elevates 23AndMe $3.5Bn IPO
23andMe is teaming up with blank check company VG Acquisition Corp to go public, making the move into personalized health care.
You may also be interested in...
Sample-collection kit and testing firms acknowledge regulatory approval for OTC sales can be as complicated as the technology behind their products. But consumers have OTC access to numerous at-home collection kits for tests for indications of diseases or medical conditions as well as for genealogy. Kits approved for testing for influenzas or other infections also should become available OTC, say industry stakeholders.
Pixel kit allows users to send nasal swab samples to be tested with LabCorp’s a real-time reverse transcription polymerase chain reaction test. Health care providers will call consumers who test positive; negative test results will be delivered by email or through LabCorp’s online portal.
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?